Author:
Wallis Robert S,Maeurer Markus,Mwaba Peter,Chakaya Jeremiah,Rustomjee Roxana,Migliori Giovanni Battista,Marais Ben,Schito Marco,Churchyard Gavin,Swaminathan Soumya,Hoelscher Michael,Zumla Alimuddin
Funder
German Ministry for Science and Education
Bill & Melinda Gates Foundation
South Africa Medical Research Council
USAID
US National Institutes of Health
Vetenskapsradet
Vinnova
Heart and Lung Foundation, Sweden
European & Developing Countries Clinical Trials Partnership
Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA)
European Union FW7
European Developing Countries
National Institute for Health Research Biomedical Research Centre at UCL Hospital (London, UK)
Reference116 articles.
1. Global tuberculosis report 2015;Anderson,2015
2. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients;Heinrich;J Antimicrob Chemother,2015
3. Boeree MJ, Hoelscher M. High-dose rifampin, SQ109, and moxifloxacin for treating TB: the PanACEA MAMS-TB trial. Conference on Reteroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23–26, 2015. Session O-7: abstr 95LB.
4. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial;Dorman;Am J Respir Crit Care Med,2015
5. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Cited by
232 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献